Related Experiment Video
Updated: Feb 6, 2026
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Yongkun Sun1, Feng Du2, Ming Gao3
11 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China .
Background:
The prognosis of advanced or metastatic medullary thyroid carcinoma (MTC) is poor, and there are few therapeutic options. Anlotinib has previously shown promising antitumor activity on MTC in preclinical models and a Phase I study. This Phase II clinical trial was devised to confirm the antitumor activity of anlotinib in patients with advanced or metastatic MTC.
Methods:
Patients with unresectable locally advanced or metastatic MTC received once daily oral anlotinib 12 mg, two weeks on/one week off, until disease progression, death, unacceptable toxicity, or withdrawal of consent for any reason. The dose was adjusted on the basis of observed toxicity. The primary endpoint was progression-free survival (PFS).
Results:
Fifty-eight patients received anlotinib treatment. The primary endpoint PFS has not yet been reached at the time of analysis. On the basis of investigator assessments, 56.9% of patients experienced a partial response. PFS rate at 48 weeks was 85.5%. Forty-five patients had a ≥50% decrease in serum calcitonin concentration from baseline. The most common adverse events were hand-foot syndrome, hypertriglyceridemia, cholesterol elevation, fatigue, and proteinuria.
Conclusions:
Anlotinib demonstrated a durable antitumor activity with a manageable adverse event profile in locally advanced or metastatic MTC.
Insights
Anlotinib shows promising results for advanced medullary thyroid carcinoma (MTC). This Phase II trial indicates durable antitumor activity and a manageable safety profile for patients with metastatic MTC.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Medullary thyroid carcinoma (MTC) has a poor prognosis with limited treatment options for advanced or metastatic disease.
- Anlotinib has demonstrated potential antitumor effects in preclinical and Phase I studies for MTC.
- This Phase II trial aimed to validate anlotinib's efficacy in patients with advanced or metastatic MTC.
Purpose of the Study:
- To confirm the antitumor activity of anlotinib in patients with advanced or metastatic medullary thyroid carcinoma.
- To evaluate the progression-free survival (PFS) in patients treated with anlotinib.
- To assess the safety and tolerability of anlotinib in this patient population.
Main Methods:
- A Phase II clinical trial involving patients with unresectable locally advanced or metastatic MTC.
- Anlotinib was administered orally at 12 mg daily (2 weeks on/1 week off) until disease progression or unacceptable toxicity.
- The primary endpoint was progression-free survival (PFS), with dose adjustments based on toxicity.
Main Results:
- Fifty-eight patients were treated with anlotinib; PFS has not yet been reached.
- Investigator assessments showed a partial response in 56.9% of patients, with an 85.5% PFS rate at 48 weeks.
- Forty-five patients achieved a ≥50% decrease in serum calcitonin; common adverse events included hand-foot syndrome and hypertriglyceridemia.
Conclusions:
- Anlotinib exhibits durable antitumor activity in patients with advanced or metastatic medullary thyroid carcinoma.
- The drug presents a manageable adverse event profile, supporting its potential as a therapeutic option.
- Further investigation may solidify anlotinib's role in MTC treatment strategies.
Related Concept Videos
02:56Treatment Resistant Cancers
01:23The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
01:18Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
01:20Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
00:56Extraction: Advanced Methods